Publication & Citation Trends
Publications
0 total
A Randomized Phase 2 Study of Daratumumab, Lenalidomide, Ixazomib, and Dexamethasone in Transplant-Ineligible/Deferred Patients with Newly Diagnosed Multiple Myeloma: Alliance Foundation Trial 41
Cited by 0
Semantic Scholar
Efficacy of Mezigdomide Plus Dexamethasone and Bortezomib or Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma by Line of Therapy: Results from the Phase 1/2 CC-92480-MM-002 Trial
Cited by 0
Semantic Scholar
Mezigdomide (MEZI) in Novel Targeted Combinations for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the Phase 1/2 CA057-003 Trial
Cited by 0
Semantic Scholar
Mezigdomide (MEZI) in Novel Combinations Effectively Reactivates Immune System in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Including those after T-Cell–Redirecting Therapies (TCRT)
Cited by 0
Semantic Scholar
Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Cited by 0
Semantic Scholar
POSTER: MM-552 Mezigdomide (MEZI) in Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Updated Results From the CA057-003 Trial
Cited by 0
Semantic Scholar
Exploratory Analyses of Progression-Free Survival (PFS) with Lenalidomide-Bortezomib-Dexamethasone (RVd) Alone/RVd+ASCT by Duffy genotype in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM)
Cited by 0
Semantic Scholar
MM-552: Mezigdomide (MEZI) in Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Updated Results From the CA057-003 Trial
Cited by 0
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(1542)
Protein Degradation and Inhibitors
(719)
Peptidase Inhibition and Analysis
(438)
Cancer Treatment and Pharmacology
(243)
Ubiquitin and proteasome pathways
(200)
Affiliations
Broad Institute
Dartmouth College
American Society For Engineering Education
Boston University
Northwestern University